High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty

Technische Universität Dresden22 enrolled

Overview

The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.

Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Arterial Occlusive Diseases

Interventions

candesartan (drug) or quinapril (drug)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male and female * peripheral occlusive arterial disease Stad IIb Fontaine classification Exclusion Criteria: * patients with lesions not available for PTA * renal insufficiency * patients on calcium-antagonists

Locations (1)

Chemnitz Hospital, Dept. of Internal Medicine I

Chemnitz, Germany

Outcomes

Primary Outcomes

Restenosis/reintervention after 6 months

Secondary Outcomes

pain-free walking distance

crurobrachial pressure ratios

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.